1. Home
  2. DKL vs SUPN Comparison

DKL vs SUPN Comparison

Compare DKL & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DKL
  • SUPN
  • Stock Information
  • Founded
  • DKL 2012
  • SUPN 2005
  • Country
  • DKL United States
  • SUPN United States
  • Employees
  • DKL N/A
  • SUPN N/A
  • Industry
  • DKL Natural Gas Distribution
  • SUPN Biotechnology: Pharmaceutical Preparations
  • Sector
  • DKL Energy
  • SUPN Health Care
  • Exchange
  • DKL Nasdaq
  • SUPN Nasdaq
  • Market Cap
  • DKL 2.3B
  • SUPN 1.9B
  • IPO Year
  • DKL N/A
  • SUPN 2012
  • Fundamental
  • Price
  • DKL $43.74
  • SUPN $31.70
  • Analyst Decision
  • DKL Buy
  • SUPN Hold
  • Analyst Count
  • DKL 4
  • SUPN 2
  • Target Price
  • DKL $44.25
  • SUPN $36.00
  • AVG Volume (30 Days)
  • DKL 96.4K
  • SUPN 685.5K
  • Earning Date
  • DKL 08-05-2025
  • SUPN 08-05-2025
  • Dividend Yield
  • DKL 10.15%
  • SUPN N/A
  • EPS Growth
  • DKL 7.97
  • SUPN N/A
  • EPS
  • DKL 2.98
  • SUPN 1.11
  • Revenue
  • DKL $938,491,000.00
  • SUPN $667,997,000.00
  • Revenue This Year
  • DKL $21.19
  • SUPN N/A
  • Revenue Next Year
  • DKL N/A
  • SUPN $12.02
  • P/E Ratio
  • DKL $14.67
  • SUPN $28.89
  • Revenue Growth
  • DKL N/A
  • SUPN 11.82
  • 52 Week Low
  • DKL $34.59
  • SUPN $25.55
  • 52 Week High
  • DKL $45.71
  • SUPN $40.28
  • Technical
  • Relative Strength Index (RSI)
  • DKL 61.82
  • SUPN 48.95
  • Support Level
  • DKL $42.29
  • SUPN $30.93
  • Resistance Level
  • DKL $43.83
  • SUPN $32.78
  • Average True Range (ATR)
  • DKL 0.91
  • SUPN 1.00
  • MACD
  • DKL -0.05
  • SUPN -0.03
  • Stochastic Oscillator
  • DKL 81.31
  • SUPN 46.56

About DKL Delek Logistics Partners L.P. Common Units representing Limited Partner Interests

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: